US drug pricing reforms are changing fast, and policymakers want to estimate the impact on innovation. The Congressional Budget Office (CBO) simulation model used for this purpose still relies on strong simplifications of how drug development actually works. www.ohe.org/insights/is-...

Fast diagnostics can cut time to treatment in bloodstream infections, saving lives and costs. New multi-country research shows strong benefits—but health systems must adapt to realise them. @biomerieux.com www.ohe.org/publications...

ASCVD costs the world roughly $680 billion yearly in healthcare costs, yet much of this is preventable. Better management of LDL-C could avoid billions in costs and gain millions of healthy life years globally. Read more: www.ohe.org/publications...

The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases - OHE

ASCVD drives major global health and economic burden, with LDL-C responsible for up to one-third. Better prevention and management could reduce costs and save lives.

ohe.org

Biologics are changing multiple myeloma care. On-body injectors, compared to currently used manual injections, could ease the burden, streamline treatment, and free up time for patients and clinicians. www.ohe.org/publications...

Amyotrophic lateral sclerosis (ALS) is rare but devastating, with high unmet need, delayed diagnosis & huge socioeconomic burden. Investment in research & new treatments is urgent, and could offer major societal & commercial returns: www.ohe.org/publications...

Patients deserve faster cancer treatment access. APACE framework bridges gaps in Europe’s approval and reimbursement process to drive change. www.ohe.org/publications...

When thinking about relapsed acute leukemia, patients care most about responding to treatment – but quality of life and treatment convenience matter too. Preferences vary, so one size doesn’t fit all. Healthcare decisions should reflect what patients value most. www.ohe.org/publications...

Wider access to cell & gene therapies could create more than £20 billion in value over 10 years, benefiting patients, the NHS, and the UK economy. Evidence supports a coordinated system shift. Read the full report www.ohe.org/publications...

Can the NHS be turned around? Prof Anita Charlesworth says yes, but only if prevention and productivity move from vision to action. Read key takeaways from OHE’s 2025 Annual Lecture: www.ohe.org/insights/tur...

Drug shortages are growing, lasting longer, and hitting patients hard. OHE’s submission to Parliament sets out causes, risks, and reforms to strengthen UK supply chains. www.ohe.org/insights/ohe...

To close the sustainability gap, creating a health system that is both low-carbon and resilient to climate impacts must be a strategic priority woven into every NHS decision. Read more about the path to a greener NHS in this Insight by Nadine Henderson: www.ohe.org/insights/env...

Environmental sustainability in the NHS 10 Year Health Plan: The need for green - OHE

This is the second in a series of blogs about how the proposals in the recently published 10 Year Plan measure up against some of the most pressing health concerns in the UK.

ohe.org

Pain/discomfort matters most to people with acute leukemia, but cognition, tiredness, and other aspects shape daily life too. Standard tools can miss these. Capturing patient priorities ensures care and policy improve quality of life, not just clinical outcomes. www.ohe.org/publications...

Understanding the preferences of people with acute leukemia for different health outcomes - OHE

When we want to understand or measure someone’s “health-related quality-of-life”, we typically ask them to describe the problems they have with different aspects of their health. In this study, we wan...

ohe.org

Saudi Arabia is formalising #HTA, adopting value-based pricing, and restructuring #healthcare delivery. What do these changes mean for #marketaccess and #policy in the region? Read our latest insight: www.ohe.org/insights/sau...

Around the World in HTAs: Saudi Arabia – Navigating the healthcare and HTA landscape - OHE

The next stop in our around the world in HTAs adventure is Saudi Arabia. This blog breaks down how the Kingdom is reshaping access to new health technologies through regulatory reform, a formal HTA fr...

ohe.org

It is Frontotemporal Dementia Awareness Week. OHE is contributing to the PREDICT-FTD consortium, which aims to advance a biomarker-based diagnosis of frontotemporal dementia. www.ohe.org/insights/the-true-cost-and-burden-of-frontotemporal-dementia-early-insights-into-a-pressing-challenge/

The NHS 10 Year Health Plan puts prevention at the centre. Misaligned incentives, behavioural barriers, and risks of widening inequalities raise the question: can prevention truly move from ambition to action? Find out: www.ohe.org/insights/pre...

China’s evolving HTA system is transforming access to medicines for 1.4B people. 700+ drugs added to the NRDL since 2017, but there are still challenges like transparency and data gaps. Read the insight:

Climate action is health action. Health economics can help shape smarter, fairer decisions – from green #HTA to valuing co-benefits of #climatepolicy. www.ohe.org/insights/cli...

What is STRIDES? A new #framework to capture the full value of #AMR diagnostics in tackling #antimicrobial resistance. Read more on how #diagnostics can help fight AMR: www.ohe.org/insights/fro...

How can we use health economics to inform climate-related policy without needing new frameworks? 📆 8 July 2025 🕛 10:00 BST 📍 Virtual event Register here: www.ohe.org/events/valui... #healtheconomics #climatechange #sustainability #publichealth

Health reforms in the Middle East are bold, fast, and values-driven. #HTA, workforce, and #pricing models are being reimagined, read our insight on what this means for #healtheconomists: www.ohe.org/insight/heal...

There is a range of ways ex-US payers and pharma companies might respond to President Trump’s “Most Favoured Nation” drug pricing. Will any of them work to lower #US drug prices? Read more: www.ohe.org/insight/the-trump-administrations-us-drug-pricing-proposal-what-will-happen-next/

New insight: 68% of OECD countries formally use #QALYs in pricing decisions, but practices vary. How consistent is economic evaluation across borders? www.ohe.org/insight/how-... #HTA #healtheconomics

New report on STRIDES—a framework to better value AMR #diagnostics. #Diagnostics are key to tackling #AMR, but #policy still overlooks their impact. Read more: www.ohe.org/publications...

Argentina plans a new national #HTA agency, ANEFiTS. A big step for evidence-based #policy, but key questions on governance, transparency & legal power remain. Read more: www.ohe.org/insight/arou...

New insight: a substantial proportion of these medicines do not deliver their intended therapeutic benefits for the individuals taking them, due to genetic variations. ##pharmacogenomics #CERSI www.ohe.org/insight/pharmacogenomics-testing-a-crucial-piece-to-unlocking-the-full-value-of-medicines/

Vaccines return up to 19x their cost, but adult #immunisation is undervalued. Our new insight calls for long-term investment to boost health, productivity & system resilience. www.ohe.org/insight/prevention-pays-off-so-why-arent-we-doing-more-of-it/

President Trump says the rest of the world “free rides” on the #US – and wants to peg US #drugprices to other countries’. This isn’t a new idea – but what might be different with his latest Executive Order? Read more: www.ohe.org/insight/the-...

New OHE report: Europe is off-track to meet 2030 #HIV eradication targets. Rising diagnoses, late testing & mounting costs demand urgent action. We highlight key barriers, the cost of complacency & solutions. Read more: www.ohe.org/publications... #publichealth #healtheconomics

How can the #UK prepare for an #ageingsociety? OHE’s submission to a #parliamentary inquiry stressed that keeping as many people as healthy and productive as possible – for as long as possible – is a requisite measure in addressing a shrinking #workforce. Read more: www.ohe.org/insight/offi...

Kenya is making progress on using evidence to guide healthcare decisions. New reforms embed #HTA in #policy, but challenges in capacity, funding and transparency remain. www.ohe.org/insight/arou...